Contineum Therapeutics (CTNM) Earnings Date, Estimates & Call Transcripts $6.47 -0.26 (-3.86%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.57 +0.10 (+1.61%) As of 08/8/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Contineum Therapeutics Earnings Summary Contineum Therapeutics posted Q2 2025 earnings on August 5, 2025, reporting an EPS of -$0.62, which missed analysts' consensus estimates of -$0.56 by $0.06. With a trailing EPS of -$2.20, Contineum Therapeutics' earnings are expected to grow next year, from ($2.01) to ($1.87) per share. Upcoming Q3 Earnings DateAug. 12Before Market OpensEstimatedConsensus EPS (Aug. 5) -$0.56 Actual EPS (Aug. 5) -$0.62 Missed By -$0.06 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)CTNM Upcoming EarningsContineum Therapeutics' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules. Powered by Get Contineum Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCTNM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Contineum Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ3 20251-$0.35-$0.35-$0.35Q4 20251-$0.36-$0.36-$0.36 2025 2 -$0.71 -$0.71 -$0.71 Q1 20261-$0.36-$0.36-$0.36Q2 20261-$0.36-$0.36-$0.36Q3 20261-$0.35-$0.35-$0.35Q4 20261-$0.35-$0.35-$0.35 Contineum Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/12/2025(Estimated)--------8/5/2025Q2 2025-$0.56-$0.62 -$0.06-$0.62$7.50M-5/14/2025Q1 2025-$0.56-$0.62 -$0.06-$0.62$7.50M-11/6/2024--$0.41-$0.40+$0.01-$0.40--8/13/2024--$0.37-$0.39 -$0.02-$0.39--5/16/2024Q1 2024-$0.53-$3.55 -$3.02-$3.55-- Contineum Therapeutics Earnings - Frequently Asked Questions When is Contineum Therapeutics' earnings date? Contineum Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 12th, 2025 based off last year's report dates. Learn more on CTNM's earnings history. Did Contineum Therapeutics beat their earnings estimates last quarter? In the previous quarter, Contineum Therapeutics (NASDAQ:CTNM) missed the analysts' consensus estimate of ($0.56) by $0.06 with a reported earnings per share (EPS) of ($0.62). Learn more on analysts' earnings estimate vs. CTNM's actual earnings. How much revenue does Contineum Therapeutics generate each year? Contineum Therapeutics (NASDAQ:CTNM) has a recorded annual revenue of $50 million. How much profit does Contineum Therapeutics generate each year? Contineum Therapeutics (NASDAQ:CTNM) has a recorded net income of -$42.26 million. CTNM has generated -$2.20 earnings per share over the last four quarters. What is Contineum Therapeutics' EPS forecast for next year? Contineum Therapeutics' earnings are expected to grow from ($2.01) per share to ($1.87) per share in the next year. More Earnings Resources from MarketBeat Related Companies Phathom Pharmaceuticals Earnings Results Keros Therapeutics Earnings Results Taysha Gene Therapies Earnings Results Organogenesis Earnings Results Tyra Biosciences Earnings Results Xencor Earnings Results Tourmaline Bio Earnings Results Prime Medicine Earnings Results Bicycle Therapeutics Earnings Results Theravance Biopharma Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally This page (NASDAQ:CTNM) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts